PAMAM Dendrimers Mediate siRNA Delivery to Target Hsp27 and Produce Potent Antiproliferative Effects on Prostate Cancer Cells

RNA interference (RNAi) holds great promise for the treatment of inherited and acquired diseases, provided that safe and efficient delivery systems are available. Herein we report that structurally flexible triethanolamine (TEA) core PAMAM dendrimers are able to deliver an Hsp27 siRNA effectively into prostate cancer (PC‐3) cells by forming stable nanoparticles with siRNA, protecting the siRNA nanoparticles from enzymatic degradation, and enhancing cellular uptake of siRNA. The Hsp27 siRNA resulted in potent and specific gene silencing of heat‐shock protein 27, an attractive therapeutic target in castrate‐resistant prostate cancer. Silencing of the hsp27 gene led to induction of caspase‐3/7‐dependent apoptosis and inhibition of PC‐3 cell growth in vitro. In addition, the siRNA–dendrimer complexes are non‐cytotoxic under the conditions used for siRNA delivery. Altogether, TEA core PAMAM dendrimer‐mediated siRNA delivery, in combination with RNAi that specifically targets Hsp27, may constitute a promising approach for combating castrate‐resistant prostate cancer, for which there is no efficacious treatment.

[1]  Leaf Huang,et al.  Overcoming the inhibitory effect of serum on lipofection by increasing the charge ratio of cationic liposome to DNA , 1997, Gene Therapy.

[2]  Cheng-Cai Zhang,et al.  Importance of size-to-charge ratio in construction of stable and uniform nanoscale RNA/dendrimer complexes. , 2007, Organic & biomolecular chemistry.

[3]  E. Gallagher,et al.  Hormone-refractory prostate cancer: a shifting paradigm in treatment. , 2006, Clinical journal of oncology nursing.

[4]  R. Pomerantz,et al.  RNA interference: on the road to an alternate therapeutic strategy! , 2003, Reviews in medical virology.

[5]  M. Gleave,et al.  Small interference RNA targeting heat‐shock protein 27 inhibits the growth of prostatic cell lines and induces apoptosis via caspase‐3 activation in vitro , 2006, BJU international.

[6]  Ling Peng,et al.  PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. , 2006, Chemical communications.

[7]  M. Gleave,et al.  Heat Shock Protein 27 Increases after Androgen Ablation and Plays a Cytoprotective Role in Hormone-Refractory Prostate Cancer , 2004, Cancer Research.

[8]  F. Szoka,et al.  Polyamidoamine cascade polymers mediate efficient transfection of cells in culture. , 1993, Bioconjugate chemistry.

[9]  Judy Lieberman,et al.  Interfering with disease: a progress report on siRNA-based therapeutics , 2007, Nature Reviews Drug Discovery.

[10]  Daniel G. Anderson,et al.  Biodegradable polymeric vectors for gene delivery to human endothelial cells. , 2006, Bioconjugate chemistry.

[11]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[12]  R. Salvioni,et al.  Treatment Options in Hormone-refractory Metastatic Prostate Carcinoma , 2004, Tumori.

[13]  William A. Goddard,et al.  Starburst Dendrimers: Molecular‐Level Control of Size, Shape, Surface Chemistry, Topology, and Flexibility from Atoms to Macroscopic Matter , 1990 .

[14]  Taylor Murray,et al.  Cancer Statistics, 2001 , 2001, CA: a cancer journal for clinicians.

[15]  J. Baker,et al.  Efficient transfer of genetic material into mammalian cells using Starburst polyamidoamine dendrimers. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Mu Xiao,et al.  Cooperative binding and self-assembling behavior of cationic low molecular-weight dendrons with RNA molecules. , 2006, Organic & biomolecular chemistry.

[17]  John J. Rossi,et al.  Strategies for silencing human disease using RNA interference , 2007, Nature Reviews Genetics.

[18]  I. Tannock,et al.  Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. , 2004, The New England journal of medicine.

[19]  Francis C Szoka,et al.  Designing dendrimers for biological applications , 2005, Nature Biotechnology.

[20]  J. Rossi,et al.  RNAi therapeutics: principles, prospects and challenges. , 2007, Advanced drug delivery reviews.

[21]  Ling Peng,et al.  Polycationic dendrimers interact with RNA molecules: polyamine dendrimers inhibit the catalytic activity of Candida ribozymes. , 2005, Chemical communications.

[22]  Guy Riddihough,et al.  In the Forests of RNA Dark Matter , 2005, Science.

[23]  S. Betigeri,et al.  Surface-modified and internally cationic polyamidoamine dendrimers for efficient siRNA delivery. , 2008, Bioconjugate chemistry.

[24]  J. Neoptolemos,et al.  Heat shock protein expression independently predicts clinical outcome in prostate cancer. , 2000, Cancer research.

[25]  M. Gleave,et al.  Increased Hsp27 after androgen ablation facilitates androgen-independent progression in prostate cancer via signal transducers and activators of transcription 3-mediated suppression of apoptosis. , 2005, Cancer research.

[26]  Ling Peng,et al.  Propagation of structural deviations of poly(amidoamine) fan-shape dendrimers (generations 0-3) characterized by MALDI and electrospray mass spectrometry , 2007 .

[27]  R. Juliano,et al.  Tat-Conjugated PAMAM Dendrimers as Delivery Agents for Antisense and siRNA Oligonucleotides , 2005, Pharmaceutical Research.

[28]  S. Jockusch,et al.  An EPR Study of the Interactions between Starburst Dendrimers and Polynucleotides , 1999 .

[29]  Z. Paroo,et al.  Challenges for RNAi in vivo. , 2004, Trends in biotechnology.

[30]  F. Szoka,et al.  In vitro gene delivery by degraded polyamidoamine dendrimers. , 1996, Bioconjugate chemistry.

[31]  D. Tomalia,et al.  Dendrimers as multi-purpose nanodevices for oncology drug delivery and diagnostic imaging. , 2007, Biochemical Society transactions.

[32]  D. A. Tomalia,et al.  Starburst‐Dendrimere: Kontrolle von Größe, Gestalt, Oberflächenchemie, Topologie und Flexibilität beim Übergang von Atomen zu makroskopischer Materie , 1990 .

[33]  Hidetoshi Arima,et al.  Evaluation of polyamidoamine dendrimer/alpha-cyclodextrin conjugate (generation 3, G3) as a novel carrier for small interfering RNA (siRNA). , 2007, Journal of controlled release : official journal of the Controlled Release Society.